Provided by Tiger Trade Technology Pte. Ltd.

Alto Neuroscience

20.11
-0.5200-2.52%
Post-market: 20.110.00000.00%17:42 EST
Volume:165.85K
Turnover:3.29M
Market Cap:624.74M
PE:-8.72
High:20.55
Open:19.88
Low:18.56
Close:20.63
52wk High:21.56
52wk Low:1.60
Shares:31.07M
Float Shares:23.99M
Volume Ratio:1.04
T/O Rate:0.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3058
EPS(LYR):-2.4970
ROE:-45.01%
ROA:-24.48%
PB:5.60
PE(LYR):-8.05

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 17, 2025

Alto Neuroscience Initiated at Buy by BTIG

Dow Jones
·
Nov 17, 2025

Alto Neuroscience initiated with a Buy at BTIG

TIPRANKS
·
Nov 17, 2025

Stifel Nicolaus Keeps Their Buy Rating on Alto Neuroscience, Inc. (ANRO)

TIPRANKS
·
Nov 17, 2025

Alto Neuroscience, Inc.: Promising Future with Strategic Advancements and Strong Financial Position

TIPRANKS
·
Nov 15, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 14, 2025

Promising Future for Alto Neuroscience: Buy Rating Backed by Strong Financials and Clinical Advancements

TIPRANKS
·
Nov 13, 2025

Alto Neuroscience’s ALTO-207: A Promising Candidate for Treatment-Resistant Depression with Significant Financial Projections

TIPRANKS
·
Nov 13, 2025

Alto Neuroscience Is Maintained at Buy by Jefferies

Dow Jones
·
Nov 13, 2025

Wedbush Adjusts Alto Neuroscience Price Target to $13 From $12, Maintains Neutral Rating

MT Newswires Live
·
Nov 13, 2025

Alto Neuroscience price target raised to $25 from $15 at Jefferies

TIPRANKS
·
Nov 12, 2025

Alto Neuroscience Unveils Precision Medicine Strategy for Mental Health Disorders

Reuters
·
Nov 12, 2025

Alto Neuroscience Q3 EPS $(0.52) Beats $(0.67) Estimate

Benzinga
·
Nov 12, 2025

Alto Neuroscience reports strong cash position and advances clinical trials for neuropsychiatric treatments

Reuters
·
Nov 12, 2025

Alto Neuroscience Inc: Topline Data for Phase 2 Trials of Alto-101 in Cias Expected 1Q 2026 and Alto-300 in Mdd Expected Mid-2026

THOMSON REUTERS
·
Nov 12, 2025

Alto Neuroscience : on Track to Initiate Phase 2B Trial in First Half of 2026 and Phase 3 Trial by Early 2027 for Alto-207

THOMSON REUTERS
·
Nov 12, 2025

NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days

prnewswire
·
Nov 11, 2025

Alto Neuroscience’s ALTO-300 Study: A Potential Game-Changer in Depression Treatment

TIPRANKS
·
Oct 28, 2025

Alto Neuroscience Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 24, 2025

Alto Neuroscience, Inc. : H.c. Wainwright Raises Target Price to $50 From $10

THOMSON REUTERS
·
Oct 24, 2025